Austin, TX Clinical Trials Report — June 2026

For Austin residents exploring clinical trial participation, June 2026 presents both urgent opportunities and significant new research avenues. With a total of **653** clinical trials currently recruiting across **396** research facilities in Austin, there are numerous ways to contribute to medical advancements.

Act quickly if you are considering participating in a clinical trial, as **33** studies are scheduled to close their enrollment within the next **90** days. This includes **5** trials that are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition before these opportunities conclude.

Impending Deadlines for Key Health Areas

Trials closing soon cover a range of conditions, making prompt action important for interested patients. Conditions with trials nearing their enrollment deadlines include:

• Cancer (**3** trials)
• Metastatic cancer (**2** trials)
• Healthy adults (**2** trials)
• Non-small cell lung cancer (**2** trials)
• Prosthesis user (**2** trials)
• Heart failure (**2** trials)
• Advanced solid tumor (**2** trials)
• Amputation; traumatic, leg, lower (**1** trial)
• Amputation (**1** trial)
• Aggression (**1** trial)

New Research Opportunities Emerge in Austin

This month, Austin welcomed **16** new clinical trials, a slight decrease from the **18** trials that opened in May 2026. These new studies are predominantly drug trials, with **13** new drug trials, **2** other types of studies, and **1** device trial. The focus of these new trials spans several common health concerns.

Conditions with the most new trials this month include:

• Overweight (**4** trials)
• Obesity (**4** trials)
• Migraine (**2** trials)
• Chronic pain (**2** trials)
• Chronic weight management (**2** trials)

Notable new Phase 3 trials from major sponsors are now recruiting in Austin, offering participants access to cutting-edge research:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This Phase 3 study aims to enroll **3,600** participants globally to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily for weight management.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 study seeking **1,100** participants. This trial will evaluate the long-term efficacy, safety, and tolerability of aleniglipron in individuals with overweight or obesity and Type 2 Diabetes Mellitus.
• Kallyope Inc. is leading NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3, double-blind, randomized study aims for **1,800** participants to assess the efficacy, safety, and tolerability of elismetrep for acute migraine treatment.
• Another study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study will evaluate the long-term safety and tolerability of intermittent use of elismetrep in **1,000** participants.
• Novo Nordisk A/S is sponsoring NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This Phase 3 study seeks **650** participants to compare the safety and effectiveness of zenagamtide against semaglutide for excess body weight.
• Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This observational study will collect urine and tumor biospecimens from **2,500** patients for bladder cancer detection and surveillance.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical research. Of the **16** new trials launched this month, **1** is actively seeking healthy volunteers. Across Austin, a total of **58** clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Austin's Leading Research Facilities

Austin is home to several prominent research facilities that consistently run a high volume of clinical trials, making them key destinations for individuals seeking to participate in medical research:

• Dell Children's Medical Center of Central Texas (**35** trials)
• Research Site (**24** trials)
• University of Texas at Austin (**19** trials)
• The University of Texas at Austin (**18** trials)
• Texas Cardiac Arrhythmia Research Foundation (**13** trials)
• NEXT Austin (**11** trials)
• FutureSearch Trials of Neurology (**10** trials)
• Dell Children's Medical Center (**10** trials)
• GSK Investigational Site (**10** trials)
• Austin Heart (**10** trials)
• Austin Retina Associates (**8** trials)
• Texas Oncology - Central South (**8** trials)

These facilities offer a broad spectrum of research, from pediatric care at Dell Children's Medical Center to specialized areas like cardiology at Austin Heart and Texas Cardiac Arrhythmia Research Foundation, and oncology at Texas Oncology - Central South.

Broadening Your Search: Nearby Texas Options

While Austin offers a robust selection of clinical trial opportunities, individuals in Central Texas may also find options in other major cities across the state. Nearby cities with active trials include Houston (**46** trials), San Antonio (**28** trials), Dallas (**24** trials), Fort Worth (**5** trials), McKinney (**4** trials), Plano (**3** trials), El Paso (**3** trials), and Brownsville (**3** trials).

Participation in clinical trials is open to a diverse range of individuals. Of the new trials launched this month, **13** include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, **2** new trials are female-only. Industry sponsors like Kallyope Inc. (**2** trials), Eli Lilly and Company (**2** trials), Novo Nordisk A/S (**2** trials), and Gasherbrum Bio, Inc. (**2** trials) are driving significant research efforts in Austin, accounting for **13** of the new trials.

As we move through June, Austin's growing research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.